New Formulation for Nasal Delivery of Peptides and Small Molecules to the CNS

Domb Abraham, HUJI, School of Medicine - IMRIC, School of Pharmacy- Institute for Drug Research


Emulsification in aqueous media is not effective for the encapsulation of hydrophilic drugs. Peptides and proteins may deteriorate when exposed to aqueous-organic interfaces

Neuropeptides are potent CNS neuromodulators and have many potential clinical uses.

Currently no neuropeptides are being used to treat CNS disorders due to their lack of BBB penetration and rapid metabolism in nearly all tissue compartments.

Our Innovation

A composition of small nanoparticles, containing an active agent such as peptides proteins small water soluble drugs and hydrophobic drugs, incorporated in a biodegradable solid lipid.

  • Easy to separate dry powder formulation
  • A dry powder formulation which is fast dispersed in water with desirable drug release
  • Fast disperse to water into uniform nano-dispersion
  • Enhancement of CNS neuropeptide delivery and site specific bioavailability of CNS neuropeptide: (1) Non-immunogenic, non-mitotic, enhances olfactory nerve uptake, protect neuropeptide against metabolism, (2) Reproducible technique for largescale production.


  • The researcher discovered small nanoparticles to be effective in alleviation of depression and epilepsy but its entry into brain is limited due to its hydrophilic nature and large size as these properties make it unsuitable to pass through BBB.
  • Nose to brain delivery was found to be a potential route for brain delivery bypassing the brain blood barrier. Nanoparticles of sufficiently small size could be transported via axonal pathway through the olfactory bulb into the olfactory cortex and from there to the caudal pole of the cerebral hemisphere, cerebrum and the cerebellum.
  • An effective treatment for CNS disorders will require sustained action, therefore, a delivery of polymeric nanoparticles will provide a more prolonged release.

Applications for use:

  • Potentially effective treatment for CNS disorders like depression and epilepsy
  • The formulation could be used as a promising protein and peptide drug carriers for drug delivery systems.


Fig. 1: Intranasal delivery of neuropeptides loaded


Contact for more information:

Mel Larrosa
VP Business Development Healthcare
Contact ME: